多発性骨髄腫に対するアンチ-B細胞成熟抗原バイスペシフィック抗体
Nitya S Ramadoss1, Andrew D Schulman1, Sei-hyun Choi
1†California Institute for Biomedical Research, 11119 North Torrey Pines Road, Suite 100, La Jolla, California 92037, United States.
Journal of the American Chemical Society
|April 1, 2015
まとめ
B細胞成熟抗原 (BiFab-BCMA) を標的にする新しい双特定抗体は,T細胞をリダイレクトすることによって多発性骨髄腫細胞を効果的に排除します. この免疫療法は,CAR-T-BCMAに匹敵する強力な活性を示し,有望な治療戦略を提供します.
科学分野:
- 免疫学 免疫学とは
- 腫瘍学 腫瘍学
- バイオテクノロジー バイオテクノロジー
背景:
- 多発性骨髄腫の治療は,薬剤耐性による課題に直面しています.
- 新しい免疫療法の開発は,耐性を克服するために不可欠です.
- B細胞成熟抗原 (BCMA) は多発性骨髄腫における重要な標的である.
研究 の 目的:
- 多発性骨髄腫に対するBCMA (BiFab-BCMA) を標的にするバイスペシフィック抗体の開発と評価.
- BiFab-BCMAの有効性と効力を in vitroおよびin vivoで評価する.
- BiFab-BCMAを他のBCMAを標的とした治療法と比較する.
主な方法:
- BCMAを標的にする双特定抗体 (BiFab-BCMA) の開発.
- BCMA陽性多発性骨髄腫細胞のT細胞リダイレクトと溶解のインビトロ評価.
- 多発性骨髄腫のオーソトピック異種移植モデルにおけるin vivo評価.
- CS1を標的とするバイスペシフィック抗体 (BiFab-CS1) と,抗BCMAキメリック抗原受容体T細胞療法 (CAR-T-BCMA) との比較.
主要な成果:
- BiFab-BCMAは,多発性骨髄腫細胞の強力で特異的な溶解を示した.
- これはBiFab-CS1.1よりも20倍も強力でした.
- BiFab-BCMAは,T細胞を in vitroで強力に活性化し,in vivoでは腫瘍の急速な回帰を媒介した.
- 実験室内および体内での活動は,CAR-T-BCMAと比較可能でした.
結論:
- BiFab-BCMAは,多発性骨髄腫に対する強力な免疫療法です.
- T細胞を効果的にリダイレクトして悪性細胞を排除します.
- BCMAを標的にした双特定抗体は,多発性骨髄腫に対する有望な治療法である.
関連する概念動画
Hybridoma Technology
18.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.7K
B Cell Activation and Differentiation
18.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
18.7K
Diversity of Antigen Receptors
2.2K
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
2.2K


